<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<html>
 <body>
  <pubmedarticleset>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32269046
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1756-1833
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         369
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          08
         </day>
        </pubdate>
       </journalissue>
       <title>
        BMJ (Clinical research ed.)
       </title>
       <isoabbreviation>
        BMJ
       </isoabbreviation>
      </journal>
      <articletitle>
       Chloroquine and hydroxychloroquine in covid-19.
      </articletitle>
      <pagination>
       <medlinepgn>
        m1432
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1136/bmj.m1432
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Ferner
        </lastname>
        <forename>
         Robin E
        </forename>
        <initials>
         RE
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Clinical Sciences, University of Birmingham, Birmingham, UK r.e.ferner@bham.ac.uk.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Aronson
        </lastname>
        <forename>
         Jeffrey K
        </forename>
        <initials>
         JK
        </initials>
        <affiliationinfo>
         <affiliation>
          Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016421">
        Editorial
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       BMJ
      </medlineta>
      <nlmuniqueid>
       8900488
      </nlmuniqueid>
      <issnlinking>
       0959-8138
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        4QWG6N8QKH
       </registrynumber>
       <nameofsubstance ui="D006886">
        Hydroxychloroquine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        886U3H6UFF
       </registrynumber>
       <nameofsubstance ui="D002738">
        Chloroquine
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000009">
        adverse effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000187">
        drug effects
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D002738">
        Chloroquine
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000009">
        adverse effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002986">
        Clinical Trials as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004353">
        Drug Evaluation, Preclinical
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D023381">
        Endpoint Determination
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D006886">
        Hydroxychloroquine
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000009">
        adverse effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012107">
        Research Design
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <coistatement>
      Competing interests: JKA is a member of the Centre for Evidence-Based Medicine in Oxford, which jointly runs the EvidenceLive Conference with the BMJ and the Overdiagnosis Conference with some international partners, which are based on a non-profit model. He is an associate editor of BMJ Evidence Based Medicine and was until recently vice-president publications for the British Pharmacological Society. REF was until recently a member of the Birmingham, Sandwell and Solihull Area prescribing committee, is a series editor of The BMJâ€™s Therapeutic Series, and has an honorary position at University College London.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32269046
      </articleid>
      <articleid idtype="doi">
       10.1136/bmj.m1432
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32231348
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       02
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       08
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Print">
        1122-0643
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         90
        </volume>
        <issue>
         1
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          30
         </day>
        </pubdate>
       </journalissue>
       <title>
        Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
       </title>
       <isoabbreviation>
        Monaldi Arch Chest Dis
       </isoabbreviation>
      </journal>
      <articletitle>
       Emerging prophylaxis strategies against COVID-19.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.4081/monaldi.2020.1289
      </elocationid>
      <abstract>
       <abstracttext>
        The Novel corona virus 2019 which started as an outbreak in China in December 2019 has rapidly spread all over the world, such that on 11th March 2020 WHO declared this disease as pandemic. The emergency that the world faces today demands that we develop urgent and effective measures to protect people at high risk of transmission. WHO has accelerated research in diagnostics, vaccines and therapeutics for this novel coronavirus.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Agrawal
        </lastname>
        <forename>
         Sumita
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Pulmonary Medicine and Critical Care, Medipulse Hospitals, Jodhpur. drsumi84@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Goel
        </lastname>
        <forename>
         Akhil Dhanesh
        </forename>
        <initials>
         AD
        </initials>
        <affiliationinfo>
         <affiliation>
          Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur. doc.akhilgoel.aiims@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gupta
        </lastname>
        <forename>
         Nitesh
        </forename>
        <initials>
         N
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pulmonary Medicine and Critical Care and Nodal Officer (Coronavirus Outbreak), Vardhaman Mahavir Medical College and Safdarjung Hospital, New Delhi. niteshgupta2107@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Italy
      </country>
      <medlineta>
       Monaldi Arch Chest Dis
      </medlineta>
      <nlmuniqueid>
       9307314
      </nlmuniqueid>
      <issnlinking>
       1122-0643
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000669933">
        COVID-19 vaccine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D014765">
        Viral Vaccines
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        4QWG6N8QKH
       </registrynumber>
       <nameofsubstance ui="D006886">
        Hydroxychloroquine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        886U3H6UFF
       </registrynumber>
       <nameofsubstance ui="D002738">
        Chloroquine
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000472">
        pathogenicity
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018890">
        Chemoprevention
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002738">
        Chloroquine
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002986">
        Clinical Trials as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000517">
        prevention &amp; control
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006886">
        Hydroxychloroquine
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D014765">
        Viral Vaccines
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
     </meshheadinglist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        2
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        2
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32231348
      </articleid>
      <articleid idtype="doi">
       10.4081/monaldi.2020.1289
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32211771
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       03
      </month>
      <day>
       26
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1537-6591
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          24
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
       </title>
       <isoabbreviation>
        Clin. Infect. Dis.
       </isoabbreviation>
      </journal>
      <articletitle>
       Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment?
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       ciaa321
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1093/cid/ciaa321
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Guastalegname
        </lastname>
        <forename>
         Maurizio
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Infectious Diseases Unit, Jazzolino Hospital, Vibo Valentia, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Vallone
        </lastname>
        <forename>
         Alfredo
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Infectious Diseases Unit, Jazzolino Hospital, Vibo Valentia, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        24
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Clin Infect Dis
      </medlineta>
      <nlmuniqueid>
       9203213
      </nlmuniqueid>
      <issnlinking>
       1058-4838
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        15
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        27
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        27
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        27
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32211771
      </articleid>
      <articleid idtype="pii">
       5811416
      </articleid>
      <articleid idtype="doi">
       10.1093/cid/ciaa321
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32150618
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       03
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1537-6591
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          09
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
       </title>
       <isoabbreviation>
        Clin. Infect. Dis.
       </isoabbreviation>
      </journal>
      <articletitle>
       In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       ciaa237
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1093/cid/ciaa237
      </elocationid>
      <abstract>
       <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
        The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection.
       </abstracttext>
       <abstracttext label="METHODS" nlmcategory="METHODS">
        The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        Hydroxychloroquine (EC50=0.72 Î¼M) was found to be more potent than chloroquine (EC50=5.47 Î¼M) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.
       </abstracttext>
       <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
        Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.
       </abstracttext>
       <copyrightinformation>
        Â© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Yao
        </lastname>
        <forename>
         Xueting
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ye
        </lastname>
        <forename>
         Fei
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention,Â China CDC, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Miao
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cui
        </lastname>
        <forename>
         Cheng
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Baoying
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention,Â China CDC, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Niu
        </lastname>
        <forename>
         Peihua
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention,Â China CDC, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Xu
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhao
        </lastname>
        <forename>
         Li
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention,Â China CDC, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dong
        </lastname>
        <forename>
         Erdan
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Song
        </lastname>
        <forename>
         Chunli
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Orthopedics, Peking University Third Hospital, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhan
        </lastname>
        <forename>
         Siyan
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lu
        </lastname>
        <forename>
         Roujian
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention,Â China CDC, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Haiyan
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Tan
        </lastname>
        <forename>
         Wenjie
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention,Â China CDC, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Dongyang
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        09
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Clin Infect Dis
      </medlineta>
      <nlmuniqueid>
       9203213
      </nlmuniqueid>
      <issnlinking>
       1058-4838
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Chloroquine
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        25
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32150618
      </articleid>
      <articleid idtype="pii">
       5801998
      </articleid>
      <articleid idtype="doi">
       10.1093/cid/ciaa237
      </articleid>
      <articleid idtype="pmc">
       PMC7108130
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32232419
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       09
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1539-3704
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          31
         </day>
        </pubdate>
       </journalissue>
       <title>
        Annals of internal medicine
       </title>
       <isoabbreviation>
        Ann. Intern. Med.
       </isoabbreviation>
      </journal>
      <articletitle>
       Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.7326/M20-1334
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Yazdany
        </lastname>
        <forename>
         Jinoos
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Zuckerberg San Francisco General Hospital, University of California, San Francisco, California (J.Y.).
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kim
        </lastname>
        <forename>
         Alfred H J
        </forename>
        <initials>
         AHJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Washington University School of Medicine, St. Louis, Missouri (A.H.K.).
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Ann Intern Med
      </medlineta>
      <nlmuniqueid>
       0372351
      </nlmuniqueid>
      <issnlinking>
       0003-4819
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        2
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        2
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        2
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32232419
      </articleid>
      <articleid idtype="pii">
       2764199
      </articleid>
      <articleid idtype="doi">
       10.7326/M20-1334
      </articleid>
      <articleid idtype="pmc">
       PMC7138336
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Virol J. 2006 May 29;3:39
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16729896
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Discov. 2020 Mar 18;6:16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32194981
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Mar 09;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32150618
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arthritis Rheum. 2006 Oct;54(10):3284-90
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17009263
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2011 Sep;11(9):677-83
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21550310
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 1991 Jan 17;324(3):150-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         1984192
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ann Intern Med. 2020 Mar 30;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32227189
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 20;:105949
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32205204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Rheumatol. 2020 Mar;16(3):155-166
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32034323
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32247318
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       05
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1476-1645
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          03
         </day>
        </pubdate>
       </journalissue>
       <title>
        The American journal of tropical medicine and hygiene
       </title>
       <isoabbreviation>
        Am. J. Trop. Med. Hyg.
       </isoabbreviation>
      </journal>
      <articletitle>
       A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.4269/ajtmh.20-0230
      </elocationid>
      <abstract>
       <abstracttext>
        The American Society of Tropical Medicine and Hygiene.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Keshtkar-Jahromi
        </lastname>
        <forename>
         Maryam
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bavari
        </lastname>
        <forename>
         Sina
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Edge BioInnovation Consulting, Frederick, Maryland.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        03
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Am J Trop Med Hyg
      </medlineta>
      <nlmuniqueid>
       0370507
      </nlmuniqueid>
      <issnlinking>
       0002-9637
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        6
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        6
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        6
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32247318
      </articleid>
      <articleid idtype="doi">
       10.4269/ajtmh.20-0230
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32281583
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1881-7823
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Bioscience trends
       </title>
       <isoabbreviation>
        Biosci Trends
       </isoabbreviation>
      </journal>
      <articletitle>
       Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.5582/bst.2020.03072
      </elocationid>
      <abstract>
       <abstracttext>
        Drugs that are specifically efficacious against SARS-CoV-2 have yet to be established. Chloroquine and hydroxychloroquine have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19). Increasing evidence obtained from completed clinical studies indicates the prospects for chloroquine/hydroxychloroquine to treat COVID-19. More randomized control clinical studies are warranted to determine the feasibility of these two drugs in treating COVID-19.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Gao
        </lastname>
        <forename>
         Jianjun
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hu
        </lastname>
        <forename>
         Shasha
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Japan
      </country>
      <medlineta>
       Biosci Trends
      </medlineta>
      <nlmuniqueid>
       101502754
      </nlmuniqueid>
      <issnlinking>
       1881-7815
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       chloroquine
      </keyword>
      <keyword majortopicyn="N">
       hydroxychloroquine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32281583
      </articleid>
      <articleid idtype="doi">
       10.5582/bst.2020.03072
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32283236
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1097-6787
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of the American Academy of Dermatology
       </title>
       <isoabbreviation>
        J. Am. Acad. Dermatol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Does Hydroxychloroquine Combat COVID-19? A Timeline of Evidence.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       S0190-9622(20)30607-1
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.jaad.2020.04.031
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Alia
        </lastname>
        <forename>
         Erisa
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          University of CT Dermatology Department.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Grant-Kels
        </lastname>
        <forename>
         Jane M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          University of CT Dermatology Department. Electronic address: grant@uchc.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016422">
        Letter
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Am Acad Dermatol
      </medlineta>
      <nlmuniqueid>
       7907132
      </nlmuniqueid>
      <issnlinking>
       0190-9622
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Pandemic
      </keyword>
      <keyword majortopicyn="N">
       Severe Acute Respiratory Syndrome Coronavirus 2 viral infection
      </keyword>
      <keyword majortopicyn="N">
       chloroquine
      </keyword>
      <keyword majortopicyn="N">
       hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       worried well
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        03
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32283236
      </articleid>
      <articleid idtype="pii">
       S0190-9622(20)30607-1
      </articleid>
      <articleid idtype="doi">
       10.1016/j.jaad.2020.04.031
      </articleid>
      <articleid idtype="pmc">
       PMC7151328
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32217705
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       01
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       01
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Electronic">
        1095-9203
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         367
        </volume>
        <issue>
         6485
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          03
         </month>
         <day>
          27
         </day>
        </pubdate>
       </journalissue>
       <title>
        Science (New York, N.Y.)
       </title>
       <isoabbreviation>
        Science
       </isoabbreviation>
      </journal>
      <articletitle>
       Race to find COVID-19 treatments accelerates.
      </articletitle>
      <pagination>
       <medlinepgn>
        1412-1413
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1126/science.367.6485.1412
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Kupferschmidt
        </lastname>
        <forename>
         Kai
        </forename>
        <initials>
         K
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Cohen
        </lastname>
        <forename>
         Jon
        </forename>
        <initials>
         J
        </initials>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016433">
        News
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Science
      </medlineta>
      <nlmuniqueid>
       0404511
      </nlmuniqueid>
      <issnlinking>
       0036-8075
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D004338">
        Drug Combinations
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C558899">
        lopinavir-ritonavir drug combination
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        2494G1JF75
       </registrynumber>
       <nameofsubstance ui="D061466">
        Lopinavir
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        3QKI37EEHE
       </registrynumber>
       <nameofsubstance ui="C000606551">
        remdesivir
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        415SHH325A
       </registrynumber>
       <nameofsubstance ui="D000249">
        Adenosine Monophosphate
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        4QWG6N8QKH
       </registrynumber>
       <nameofsubstance ui="D006886">
        Hydroxychloroquine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        886U3H6UFF
       </registrynumber>
       <nameofsubstance ui="D002738">
        Chloroquine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        O3J8G9O825
       </registrynumber>
       <nameofsubstance ui="D019438">
        Ritonavir
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        OF5P57N2ZX
       </registrynumber>
       <nameofsubstance ui="D000409">
        Alanine
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000249">
        Adenosine Monophosphate
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000031">
        analogs &amp; derivatives
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000409">
        Alanine
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000031">
        analogs &amp; derivatives
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D035843">
        Biomedical Research
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000458">
        organization &amp; administration
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002738">
        Chloroquine
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002986">
        Clinical Trials as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000401">
        mortality
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004338">
        Drug Combinations
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006886">
        Hydroxychloroquine
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000009">
        adverse effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D061466">
        Lopinavir
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000401">
        mortality
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D019438">
        Ritonavir
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D014944">
        World Health Organization
       </descriptorname>
      </meshheading>
     </meshheadinglist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        29
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        29
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        2
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32217705
      </articleid>
      <articleid idtype="pii">
       367/6485/1412
      </articleid>
      <articleid idtype="doi">
       10.1126/science.367.6485.1412
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32194152
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1872-7913
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of antimicrobial agents
       </title>
       <isoabbreviation>
        Int. J. Antimicrob. Agents
       </isoabbreviation>
      </journal>
      <articletitle>
       Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.
      </articletitle>
      <pagination>
       <medlinepgn>
        105945
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0924-8579(20)30095-9
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.ijantimicag.2020.105945
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sahraei
        </lastname>
        <forename>
         Zahra
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: zahra.sahraei@yahoo.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Shabani
        </lastname>
        <forename>
         Minoosh
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: meinoosh53@yahoo.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Shokouhi
        </lastname>
        <forename>
         Shervin
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: shsh.50@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Saffaei
        </lastname>
        <forename>
         Ali
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: alisaffaei.ss@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Int J Antimicrob Agents
      </medlineta>
      <nlmuniqueid>
       9111860
      </nlmuniqueid>
      <issnlinking>
       0924-8579
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Chloroquine
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        26
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        09
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        21
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        21
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        21
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32194152
      </articleid>
      <articleid idtype="pii">
       S0924-8579(20)30095-9
      </articleid>
      <articleid idtype="doi">
       10.1016/j.ijantimicag.2020.105945
      </articleid>
      <articleid idtype="pmc">
       PMC7156117
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2018 Jan;149:143-149
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29175128
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Inflammopharmacology. 2015 Oct;23(5):231-69
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26246395
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arthritis Res Ther. 2018 Jul 5;20(1):133
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29976231
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19188392
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2003 Nov;3(11):722-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14592603
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32171740
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       04
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1872-7913
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          12
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of antimicrobial agents
       </title>
       <isoabbreviation>
        Int. J. Antimicrob. Agents
       </isoabbreviation>
      </journal>
      <articletitle>
       New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
      </articletitle>
      <pagination>
       <medlinepgn>
        105938
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0924-8579(20)30088-1
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.ijantimicag.2020.105938
      </elocationid>
      <abstract>
       <abstracttext>
        Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.
       </abstracttext>
       <copyrightinformation>
        Copyright Â© 2020 The Authors. Published by Elsevier B.V. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Devaux
        </lastname>
        <forename>
         Christian A
        </forename>
        <initials>
         CA
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille UniversitÃ©, IRD, APHM, MEPHI, IHU-MÃ©diterranÃ©e Infection, Marseille, France; CNRS, Marseille, France; IHU-MÃ©diterranÃ©e Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. Electronic address: christian.devaux@mediterranee-infection.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Rolain
        </lastname>
        <forename>
         Jean-Marc
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille UniversitÃ©, IRD, APHM, MEPHI, IHU-MÃ©diterranÃ©e Infection, Marseille, France; IHU-MÃ©diterranÃ©e Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Colson
        </lastname>
        <forename>
         Philippe
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille UniversitÃ©, IRD, APHM, MEPHI, IHU-MÃ©diterranÃ©e Infection, Marseille, France; IHU-MÃ©diterranÃ©e Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Raoult
        </lastname>
        <forename>
         Didier
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille UniversitÃ©, IRD, APHM, MEPHI, IHU-MÃ©diterranÃ©e Infection, Marseille, France; IHU-MÃ©diterranÃ©e Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        12
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Int J Antimicrob Agents
      </medlineta>
      <nlmuniqueid>
       9111860
      </nlmuniqueid>
      <issnlinking>
       0924-8579
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Chloroquine
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        02
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        03
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        05
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32171740
      </articleid>
      <articleid idtype="pii">
       S0924-8579(20)30088-1
      </articleid>
      <articleid idtype="doi">
       10.1016/j.ijantimicag.2020.105938
      </articleid>
      <articleid idtype="pmc">
       PMC7118659
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        J Clin Virol. 2001 Feb;20(3):131-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11166661
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Gen Virol. 1983 May;64(Pt 5):1149-56
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         6842189
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Feb 20;382(8):727-733
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31978945
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ann Ophthalmol. 1991 Aug;23(8):292-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         1952638
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2011 May;85(9):4122-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21325420
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 1988 Jun;85(12):4526-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         3380803
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 20;43(0):E019
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32075365
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2004 Jun;78(11):5642-50
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15140961
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virology. 1984 Oct 30;138(2):332-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         6093369
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 1990 Aug;34(8):1512-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         2221859
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2015 Jul;89(14):7202-13
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25926653
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2009 Jan;83(2):1026-35
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18987136
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virology. 1990 Feb;174(2):450-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         2154882
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virol J. 2006 May 29;3:39
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16729896
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20706626
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Gen Virol. 2015 Dec;96(12):3484-3492
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26459826
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arch Neurol. 1998 Sep;55(9):1248-54
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9740120
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2009 May;83(10):5148-55
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19264786
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Br Heart J. 1993 May;69(5):451-2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8518071
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Clin Virol. 2001 Feb;20(3):137-40
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11166662
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 1991 Dec;65(12):7008-11
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         1658391
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Intervirology. 1998;41(6):261-71
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         10325536
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 1994 Oct;68(10):6523-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8083990
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lupus. 2006;15(5):268-75
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16761500
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2014 Feb 22;383(9918):723-35
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23953767
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Nephrol. 2011 Oct 18;7(12):718-29
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22009248
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 1981 Jun;78(6):3605-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         6115382
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ann Acad Med Singapore. 1986 Apr;15(2):149-52
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         3752892
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2013 Feb;23(2):300-2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23208422
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2008 Feb;77(2):150-2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18055026
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Gastroenterol. 2010 Feb;45(2):195-203
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19760134
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 1987 Jan 22;316(4):191-3
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         3796692
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Vector Borne Zoonotic Dis. 2008 Dec;8(6):837-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18620511
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Host Microbe. 2017 Mar 8;21(3):356-366
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28279346
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Immunology. 1993 Sep;80(1):127-33
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8244453
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2007 Oct;30(4):297-308
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17629679
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        FASEB J. 1997 Mar;11(4):248-55
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9068613
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Immunol. 1997 May 15;158(10):4901-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9144507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2011 Jun;83(6):1058-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21503920
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2008 Feb;18(2):290-301
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18227861
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2014 May 6;111(18):6756-61
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24753610
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arch Intern Med. 1999 Jan 25;159(2):167-73
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9927100
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9065-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18550812
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19506054
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Microbiol. 2013 Dec;11(12):836-48
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24217413
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Immunology. 1993 Sep;80(1):122-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8244452
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Pharm Des. 2004;10(21):2643-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15320751
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virol J. 2005 Aug 22;2:69
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16115318
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Antimicrob Chemother. 2016 Dec;71(12):3340-3350
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27585965
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arch Virol. 1989;104(1-2):157-61
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         2923547
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2010 May;82(5):817-24
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20336760
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        AIDS Res Hum Retroviruses. 1990 Apr;6(4):481-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         1692728
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 1984 Dec;52(3):857-64
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         6492263
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Rheumatology (Oxford). 2006 Jun;45(6):703-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16418198
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Microbiol Immunol. 2014 Jun;58(6):318-26
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24773578
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2011 Sep;11(9):677-83
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21550310
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect Dis. 2001 Sep 15;184(6):770-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11517439
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841269
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2004 Mar 5;303(5663):1529-31
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14976261
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2004 Mar;48(3):747-52
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14982759
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2015 Jun;118:75-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25796972
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Exp Med. 2005 Sep 19;202(6):817-28
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16157687
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arch Virol. 1984;81(3-4):377-82
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         6148053
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochemistry. 2004 Apr 20;43(15):4538-47
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15078100
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2005 Mar;5(3):184-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15766653
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Iran J Med Sci. 2017 Mar;42(2):115-128
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28360437
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2008 Oct 9;455(7214):751-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18843360
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2014 Nov;88(22):13221-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25187545
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arch Virol. 1987;96(3-4):289-96
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         2821967
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Immunol. 2000 Aug 1;165(3):1534-40
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         10903761
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Clin Immunol. 2003 Nov;23(6):477-84
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15031635
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2019 Sep 27;294(39):14406-14421
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31399512
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25288733
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Methods Mol Biol. 2015;1282:1-23
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25720466
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2003 Nov;3(11):722-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14592603
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Vaccine. 2013 Mar 25;31(13):1717-24
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23380456
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viruses. 2016 Nov 29;8(12):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27916837
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2016 Aug 22;60(9):5492-503
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27381385
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 1998 Jul;72(7):6207-14
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9621091
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Immunol Invest. 1993 Mar;22(2):95-103
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8505072
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virology. 2011 May 10;413(2):265-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21435673
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Gen Virol. 2010 Mar;91(Pt 3):765-72
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19889926
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Immunology. 2002 Jan;105(1):83-91
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11849318
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2001 Feb;75(3):1236-51
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11152497
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Infect Genet Evol. 2012 Aug;12(6):1275-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22386853
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32293710
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1096-9071
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of medical virology
       </title>
       <isoabbreviation>
        J. Med. Virol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/jmv.25887
      </elocationid>
      <abstract>
       <abstracttext>
        COVID-19 infection and its severity can be explained by the concentration of glycosylated SARS- CoV-2 viral particles in the lung epithelium, the concentration of glycosylated angiotensin converting enzyme receptor 2 (ACE2) in the lung epithelium, and the degree and control of the pulmonary immune response to the SARS-CoV-2 spike protein at approximately day 8-10 after symptom onset, which may be related to both. Binding of ACE2 by SARS-CoV-2 in COVID-19 also suggests that prolonged uncontrolled hyperglycemia, and not just a history of diabetes mellitus, may be important in the pathogenesis of the disease. It is tempting to consider that the same mechanism acts in COVID-19 as in SARS, where an overactive macrophage M1 inflammatory response, as neutralizing antibodies to the SARS-CoV- 2 spike protein form at day 7-10, results in acute respiratory distress syndrome (ARDS) in susceptible patients. It is also allows consideration of agents, such as hydroxychloroquine, which may interfere with this overly brisk macrophage inflammatory response and perhaps influence the course of the disease, in particular those that blunt but do not completely abrogate the M1 to M2 balance in macrophage polarization, as well as viral load, which in SARS appears to be temporally related to the onset of ARDS. This article is protected by copyright. All rights reserved.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Brufsky
        </lastname>
        <forename>
         Adam
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-8080-7960
        </identifier>
        <affiliationinfo>
         <affiliation>
          UPMC Hillman Cancer Center, Magee Women's Hospital, University of Pittsburgh School of Medicine, Suite 4628, 300 Halket Street, Pittsburgh, PA, 15213.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Med Virol
      </medlineta>
      <nlmuniqueid>
       7705876
      </nlmuniqueid>
      <issnlinking>
       0146-6615
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       SARS coronavirus
      </keyword>
      <keyword majortopicyn="N">
       antibody-mediated cell-mediated cytotoxicity
      </keyword>
      <keyword majortopicyn="N">
       antiviral agents
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32293710
      </articleid>
      <articleid idtype="doi">
       10.1002/jmv.25887
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32247211
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       19
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1878-0334
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         14
        </volume>
        <issue>
         3
        </issue>
        <pubdate>
         <medlinedate>
          2020 May - Jun
         </medlinedate>
        </pubdate>
       </journalissue>
       <title>
        Diabetes &amp; metabolic syndrome
       </title>
       <isoabbreviation>
        Diabetes Metab Syndr
       </isoabbreviation>
      </journal>
      <articletitle>
       Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.
      </articletitle>
      <pagination>
       <medlinepgn>
        241-246
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S1871-4021(20)30051-5
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.dsx.2020.03.011
      </elocationid>
      <abstract>
       <abstracttext label="BACKGROUND AND AIMS" nlmcategory="OBJECTIVE">
        No drugs are currently approved for Coronavirus Disease-2019 (COVID-19), although some have been tried. In view of recent studies and discussion on chloroquine and hydroxychloroquine (HCQ), we aimed to review existing literature and relevant websites regarding these drugs and COVID-19, adverse effects related to drugs, and related guidelines.
       </abstracttext>
       <abstracttext label="AIMS AND METHODS" nlmcategory="OBJECTIVE">
        We systematically searched the PubMed database up till March 21, 2020 and retrieved all the articles published on chloroquine and HCQ and COVID-19.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19.
       </abstracttext>
       <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
        Considering minimal risk upon use, a long experience of use in other diseases, cost-effectiveness and easy availability across India, we propose that both these drugs are worthy of fast track clinical trial for treatment, and may be carefully considered for clinical use as experimental drugs. Since HCQ has been approved for treatment of diabetes in India, it should be further researched in diabetes and COVID-19, a subgroup where significant mortality has been shown.
       </abstracttext>
       <copyrightinformation>
        Copyright Â© 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Singh
        </lastname>
        <forename>
         Awadhesh Kumar
        </forename>
        <initials>
         AK
        </initials>
        <affiliationinfo>
         <affiliation>
          G. D Hospital &amp; Diabetes Institute, Kolkata, India. Electronic address: draksingh_2001@yahoo.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Singh
        </lastname>
        <forename>
         Akriti
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          College of Medicine &amp; JNM Hospital, Kalyani, Nadia, West Bengal, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Shaikh
        </lastname>
        <forename>
         Altamash
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Saifee Hospital, Mumbai, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Singh
        </lastname>
        <forename>
         Ritu
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          G. D Hospital &amp; Diabetes Institute, Kolkata, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Misra
        </lastname>
        <forename>
         Anoop
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Fortis CDOC Hospital for Diabetes and Allied Sciences, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        26
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Diabetes Metab Syndr
      </medlineta>
      <nlmuniqueid>
       101462250
      </nlmuniqueid>
      <issnlinking>
       1871-4021
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Chloroquine
      </keyword>
      <keyword majortopicyn="N">
       Diabetes
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest We hereby declare that we have no conflict of interest related to this article.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        21
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        22
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        22
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        5
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        5
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        5
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32247211
      </articleid>
      <articleid idtype="pii">
       S1871-4021(20)30051-5
      </articleid>
      <articleid idtype="doi">
       10.1016/j.dsx.2020.03.011
      </articleid>
      <articleid idtype="pmc">
       PMC7102587
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32187489
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       03
      </month>
      <day>
       25
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       03
      </month>
      <day>
       25
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Electronic">
        1533-4406
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         382
        </volume>
        <issue>
         12
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          03
         </month>
         <day>
          19
         </day>
        </pubdate>
       </journalissue>
       <title>
        The New England journal of medicine
       </title>
       <isoabbreviation>
        N. Engl. J. Med.
       </isoabbreviation>
      </journal>
      <articletitle>
       Audio Interview: New Research on Possible Treatments for Covid-19.
      </articletitle>
      <pagination>
       <medlinepgn>
        e30
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1056/NEJMe2005759
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Rubin
        </lastname>
        <forename>
         Eric J
        </forename>
        <initials>
         EJ
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Baden
        </lastname>
        <forename>
         Lindsey R
        </forename>
        <initials>
         LR
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Morrissey
        </lastname>
        <forename>
         Stephen
        </forename>
        <initials>
         S
        </initials>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016421">
        Editorial
       </publicationtype>
       <publicationtype ui="D059040">
        Video-Audio Media
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       N Engl J Med
      </medlineta>
      <nlmuniqueid>
       0255562
      </nlmuniqueid>
      <issnlinking>
       0028-4793
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000305">
        Adrenal Cortex Hormones
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000894">
        Anti-Inflammatory Agents, Non-Steroidal
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D004338">
        Drug Combinations
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D011991">
        Receptors, Virus
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C558899">
        lopinavir-ritonavir drug combination
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        2494G1JF75
       </registrynumber>
       <nameofsubstance ui="D061466">
        Lopinavir
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        4QWG6N8QKH
       </registrynumber>
       <nameofsubstance ui="D006886">
        Hydroxychloroquine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        O3J8G9O825
       </registrynumber>
       <nameofsubstance ui="D019438">
        Ritonavir
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000305">
        Adrenal Cortex Hormones
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000894">
        Anti-Inflammatory Agents, Non-Steroidal
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002986">
        Clinical Trials as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000517">
        prevention &amp; control
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000628">
        therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D003428">
        Cross Infection
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000517">
        prevention &amp; control
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D003937">
        Diagnosis, Differential
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004338">
        Drug Combinations
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006886">
        Hydroxychloroquine
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D017053">
        Infection Control
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000379">
        methods
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007251">
        Influenza, Human
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D061466">
        Lopinavir
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D005791">
        Patient Care
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011991">
        Receptors, Virus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000037">
        antagonists &amp; inhibitors
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D012121">
        Respiration, Artificial
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000009">
        adverse effects
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D019438">
        Ritonavir
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
     </meshheadinglist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        26
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32187489
      </articleid>
      <articleid idtype="doi">
       10.1056/NEJMe2005759
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32277367
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       11
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1434-9949
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical rheumatology
       </title>
       <isoabbreviation>
        Clin. Rheumatol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s10067-020-05073-9
      </elocationid>
      <abstract>
       <abstracttext>
        The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such asÂ air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such asÂ arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Pointsâ€¢ Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.â€¢ Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.â€¢ Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Misra
        </lastname>
        <forename>
         Durga Prasanna
        </forename>
        <initials>
         DP
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-5035-7396
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. durgapmisra@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Agarwal
        </lastname>
        <forename>
         Vikas
        </forename>
        <initials>
         V
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4508-1233
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gasparyan
        </lastname>
        <forename>
         Armen Yuri
        </forename>
        <initials>
         AY
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-8749-6018
        </identifier>
        <affiliationinfo>
         <affiliation>
          Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zimba
        </lastname>
        <forename>
         Olena
        </forename>
        <initials>
         O
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4188-8486
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Germany
      </country>
      <medlineta>
       Clin Rheumatol
      </medlineta>
      <nlmuniqueid>
       8211469
      </nlmuniqueid>
      <issnlinking>
       0770-3198
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Epidemiology
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       Hypothesis
      </keyword>
      <keyword majortopicyn="N">
       Immunity
      </keyword>
      <keyword majortopicyn="N">
       Pathogenesis
      </keyword>
      <keyword majortopicyn="N">
       Vaccines
      </keyword>
      <keyword majortopicyn="N">
       Vitamin D
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        24
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32277367
      </articleid>
      <articleid idtype="doi">
       10.1007/s10067-020-05073-9
      </articleid>
      <articleid idtype="pii">
       10.1007/s10067-020-05073-9
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32251731
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1872-7913
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          03
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of antimicrobial agents
       </title>
       <isoabbreviation>
        Int. J. Antimicrob. Agents
       </isoabbreviation>
      </journal>
      <articletitle>
       Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
      </articletitle>
      <pagination>
       <medlinepgn>
        105960
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0924-8579(20)30110-2
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.ijantimicag.2020.105960
      </elocationid>
      <abstract>
       <abstracttext>
        The recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) is responsible for a worldwide pandemic. Given the global health emergency, drug repositioning is the most reliable option to design an efficient therapy for infected patients without delay. The first step of the viral replication cycle [i.e. attachment to the surface of respiratory cells, mediated by the spike (S) viral protein] offers several potential therapeutic targets. The S protein uses the angiotension-converting enzyme-2 (ACE-2) receptor for entry, but also sialic acids linked to host cell surface gangliosides. Using a combination of structural and molecular modelling approaches, this study showed that chloroquine (CLQ), one of the drugs currently under investigation for SARS-CoV-2 treatment, binds sialic acids and gangliosides with high affinity. A new type of ganglioside-binding domain at the tip of the N-terminal domain of the SARS-CoV-2 S protein was identified. This domain (111-158), which is fully conserved among clinical isolates worldwide, may improve attachment of the virus to lipid rafts and facilitate contact with the ACE-2 receptor. This study showed that, in the presence of CLQ [or its more active derivative, hydroxychloroquine (CLQ-OH)], the viral S protein is no longer able to bind gangliosides. The identification of this new mechanism of action of CLQ and CLQ-OH supports the use of these repositioned drugs to cure patients infected with SARS-CoV-2. The in-silico approaches used in this study might also be used to assess the efficiency of a broad range of repositioned and/or innovative drug candidates before clinical evaluation.
       </abstracttext>
       <copyrightinformation>
        Copyright Â© 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Fantini
        </lastname>
        <forename>
         Jacques
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          INSERM UMR_S 1072, Marseille, France; Department of Biology, Aix-Marseille UniversitÃ©, Marseille, France. Electronic address: jacques.fantini@univ-amu.fr.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Di Scala
        </lastname>
        <forename>
         Coralie
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          INMED, INSERM U1249, Parc Scientifique de Luminy, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chahinian
        </lastname>
        <forename>
         Henri
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          INSERM UMR_S 1072, Marseille, France; Department of Biology, Aix-Marseille UniversitÃ©, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yahi
        </lastname>
        <forename>
         Nouara
        </forename>
        <initials>
         N
        </initials>
        <affiliationinfo>
         <affiliation>
          INSERM UMR_S 1072, Marseille, France; Department of Biology, Aix-Marseille UniversitÃ©, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        03
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Int J Antimicrob Agents
      </medlineta>
      <nlmuniqueid>
       9111860
      </nlmuniqueid>
      <issnlinking>
       0924-8579
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Chloroquine
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Ganglioside
      </keyword>
      <keyword majortopicyn="N">
       Pandemic
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       Spike
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        16
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        21
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        7
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        7
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        7
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32251731
      </articleid>
      <articleid idtype="pii">
       S0924-8579(20)30110-2
      </articleid>
      <articleid idtype="doi">
       10.1016/j.ijantimicag.2020.105960
      </articleid>
      <articleid idtype="pmc">
       PMC7128678
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32241801
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       03
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        0315-162X
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          02
         </day>
        </pubdate>
       </journalissue>
       <title>
        The Journal of rheumatology
       </title>
       <isoabbreviation>
        J. Rheumatol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       jrheum.200369
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.3899/jrheum.200369
      </elocationid>
      <abstract>
       <abstracttext>
        Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3].
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Scuccimarri
        </lastname>
        <forename>
         Rosie
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          From the Division of Pediatric Rheumatology, McGill University Health Centre, Quebec, Canada;Division of Rheumatology, Dalhousie University, Nova Scotia, Canada; Alan Edwards Pain Management Unit, McGill University Health Centre, Quebec, Canada; Division of Rheumatology, McGill University Health Centre, Quebec, Canada. Address correspondence to Mary-Ann Fitzcharles, Montreal General Hospital, McGill University Health Centre, 1650 Cedar ave, Montreal, Quebec, H3G 1A4. E-mail:mfitzcharles@sympatico.ca.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sutton
        </lastname>
        <forename>
         Evelyn
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          From the Division of Pediatric Rheumatology, McGill University Health Centre, Quebec, Canada;Division of Rheumatology, Dalhousie University, Nova Scotia, Canada; Alan Edwards Pain Management Unit, McGill University Health Centre, Quebec, Canada; Division of Rheumatology, McGill University Health Centre, Quebec, Canada. Address correspondence to Mary-Ann Fitzcharles, Montreal General Hospital, McGill University Health Centre, 1650 Cedar ave, Montreal, Quebec, H3G 1A4. E-mail:mfitzcharles@sympatico.ca.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Fitzcharles
        </lastname>
        <forename>
         Mary-Ann
        </forename>
        <initials>
         MA
        </initials>
        <affiliationinfo>
         <affiliation>
          From the Division of Pediatric Rheumatology, McGill University Health Centre, Quebec, Canada;Division of Rheumatology, Dalhousie University, Nova Scotia, Canada; Alan Edwards Pain Management Unit, McGill University Health Centre, Quebec, Canada; Division of Rheumatology, McGill University Health Centre, Quebec, Canada. Address correspondence to Mary-Ann Fitzcharles, Montreal General Hospital, McGill University Health Centre, 1650 Cedar ave, Montreal, Quebec, H3G 1A4. E-mail:mfitzcharles@sympatico.ca.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        02
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Canada
      </country>
      <medlineta>
       J Rheumatol
      </medlineta>
      <nlmuniqueid>
       7501984
      </nlmuniqueid>
      <issnlinking>
       0315-162X
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        4
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        4
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        4
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32241801
      </articleid>
      <articleid idtype="pii">
       jrheum.200369
      </articleid>
      <articleid idtype="doi">
       10.3899/jrheum.200369
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32265182
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       08
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2398-3795
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          07
         </day>
        </pubdate>
       </journalissue>
       <title>
        BJGP open
       </title>
       <isoabbreviation>
        BJGP Open
       </isoabbreviation>
      </journal>
      <articletitle>
       Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       bjgpopen20X101069
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.3399/bjgpopen20X101069
      </elocationid>
      <abstract>
       <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
        On the 11 March 2020, the World Health Organization (WHO) declared that COVID-19 was a pandemic. To date, there are no medical treatments for COVID-19 with proven effectiveness. Novel treatments and/or vaccines will take time to be developed and distributed to patients. In light of this, there has been growing interest in the use of existing medications, such as chloroquine (CQ) and hydroxychloroquine (HCQ), as potential treatments of this disease.
       </abstracttext>
       <abstracttext label="AIM" nlmcategory="OBJECTIVE">
        To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19.
       </abstracttext>
       <abstracttext label="DESIGN &amp; SETTING" nlmcategory="METHODS">
        A rapid review of the literature was conducted.
       </abstracttext>
       <abstracttext label="METHOD" nlmcategory="METHODS">
        Electronic searches in PubMed and Google Scholar were conducted on 21 March 2020. A further search was conducted in Google for relevant literature on 28 March 2020.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        There is limited evidence of in vitro activity of CQ/HCQ against SARS-CoV-2. A number of in vivo clinical trials are underway. The empirical data available from two of these trials reveal conflicting results. Both trials are characterised by small numbers of participants (
        <i>
         n
        </i>
        = 30 and
        <i>
         n
        </i>
        = 36) and suffer methodological limitations. No medium or long-term follow-up data is available.
       </abstracttext>
       <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
        At present, there is insufficient evidence to determine whether CQ/HCQ are safe and effective treatments for COVID-19. High quality, adequately powered randomised clinical trials in primary and secondary care settings are urgently required to guide policymakers and clinicians. These studies should report medium- and long-term follow-up results, and safety data.
       </abstracttext>
       <copyrightinformation>
        Copyright Â© 2020, The Authors.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Gbinigie
        </lastname>
        <forename>
         Kome
        </forename>
        <initials>
         K
        </initials>
        <affiliationinfo>
         <affiliation>
          GP and Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK Oghenekome.gbinigie@phc.ox.ac.uk.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Frie
        </lastname>
        <forename>
         Kerstin
        </forename>
        <initials>
         K
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-4717-5874
        </identifier>
        <affiliationinfo>
         <affiliation>
          Post-Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       BJGP Open
      </medlineta>
      <nlmuniqueid>
       101713531
      </nlmuniqueid>
      <issnlinking>
       2398-3795
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Chloroquine
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
      <keyword majortopicyn="N">
       general practice
      </keyword>
      <keyword majortopicyn="N">
       primary healthcare
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32265182
      </articleid>
      <articleid idtype="pii">
       bjgpopen20X101069
      </articleid>
      <articleid idtype="doi">
       10.3399/bjgpopen20X101069
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32284951
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Print">
        2328-8957
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         7
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
        </pubdate>
       </journalissue>
       <title>
        Open forum infectious diseases
       </title>
       <isoabbreviation>
        Open Forum Infect Dis
       </isoabbreviation>
      </journal>
      <articletitle>
       Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.
      </articletitle>
      <pagination>
       <medlinepgn>
        ofaa105
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1093/ofid/ofaa105
      </elocationid>
      <abstract>
       <abstracttext>
        Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.
       </abstracttext>
       <copyrightinformation>
        Â© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         McCreary
        </lastname>
        <forename>
         Erin K
        </forename>
        <initials>
         EK
        </initials>
        <identifier source="ORCID">
         0000-0001-6705-2225
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pogue
        </lastname>
        <forename>
         Jason M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Open Forum Infect Dis
      </medlineta>
      <nlmuniqueid>
       101637045
      </nlmuniqueid>
      <issnlinking>
       2328-8957
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       lopinavir/ritonavir
      </keyword>
      <keyword majortopicyn="N">
       remdesivir
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        18
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32284951
      </articleid>
      <articleid idtype="doi">
       10.1093/ofid/ofaa105
      </articleid>
      <articleid idtype="pii">
       ofaa105
      </articleid>
      <articleid idtype="pmc">
       PMC7144823
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2019 Nov 13;69(11):1903-1911
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30753384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Pharmacokinet. 1993 Nov;25(5):392-407
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         7904547
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29161116
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Clin Virol. 2004 Dec;31(4):304-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15494274
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hong Kong Med J. 2003 Dec;9(6):399-406
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14660806
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2010 Mar;84(5):2511-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20032190
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2003 Jun 4;289(21):2801-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12734147
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biosci Trends. 2020 Mar 16;14(1):64-68
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32037389
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2020 Mar 5;177:104762
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32147496
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trials. 2020 Jan 3;21(1):8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31900204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect. 2005 Aug;51(2):98-102
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16038758
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Crit Care Med. 2019 Sep;47(9):e735-e743
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31162191
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Mar 3;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32125362
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect Dis. 2015 Dec 15;212(12):1904-13
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26198719
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 29;395(10225):683-684
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32122468
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Transl Med. 2017 Jun 28;9(396):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28659436
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Med. 2006 Sep;3(9):e343
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16968120
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 28;395(10229):1054-1062
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2003 May 15;348(20):1986-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12682352
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Oncologist. 2018 Aug;23(8):943-947
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29622697
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biosci Trends. 2020 Mar 16;14(1):72-73
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32074550
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):e30-e31
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32032529
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Expert Rev Clin Immunol. 2019 Aug;15(8):813-822
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31219357
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 20;:105949
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32205204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA Intern Med. 2020 Mar 13;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32167524
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Thorax. 2004 Mar;59(3):252-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14985565
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Korean Med Sci. 2020 Feb 17;35(6):e79
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32056407
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 2017 Mar 9;60(5):1648-1661
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28124907
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Life Sci. 2020 May 1;248:117477
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32119961
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 5;382(10):929-936
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32004427
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2014 Jul;14(7):609-18
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24852376
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Mar 09;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32150618
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        mBio. 2018 Mar 6;9(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29511076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect Public Health. 2016 May-Jun;9(3):227-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27095301
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect Dis. 2017 Jan 15;215(2):171-174
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28073857
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        ACS Infect Dis. 2020 Mar 10;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32125140
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):385-91
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21876444
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2018 Aug 1;67(4):533-540
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29481659
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2019 Dec 12;381(24):2293-2303
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31774950
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2020 Apr 10;295(15):4773-4779
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32094225
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2020 Apr;20(4):398-400
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32113510
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Apr 15;70(9):1837-1844
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31925415
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 May;92(5):461-463
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32073161
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ther Drug Monit. 2011 Oct;33(5):573-82
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21912331
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 7;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32031570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2016 Mar 17;531(7594):381-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26934220
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2020 Jan 10;11(1):222
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31924756
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Emerg Infect Dis. 2004 Apr;10(4):581-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15200845
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 18;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32187464
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30592986
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18852458
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841269
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):507-513
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 4;:105932
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32145363
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2016 Jul 30;388(10043):498-503
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27209148
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2018 Feb;150:155-163
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29289665
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 2006 May 4;49(9):2845-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16640347
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Infect Control Hosp Epidemiol. 2020 Mar 13;:1-2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32167442
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chest. 2006 Jun;129(6):1441-52
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16778260
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32290293
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1422-0067
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         21
        </volume>
        <issue>
         7
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of molecular sciences
       </title>
       <isoabbreviation>
        Int J Mol Sci
       </isoabbreviation>
      </journal>
      <articletitle>
       A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       E2657
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.3390/ijms21072657
      </elocationid>
      <abstract>
       <abstracttext>
        The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2. We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation. We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic. Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety. On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety. These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses. The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including
        <i>
         favipiravir
        </i>
        , a broad-spectrum antiviral drug that interferes with the viral replication, and
        <i>
         hydroxychloroquine
        </i>
        , the repurposed antimalarial drug that interferes with the virus endosomal entry pathway. We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Tu
        </lastname>
        <forename>
         Yung-Fang
        </forename>
        <initials>
         YF
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chien
        </lastname>
        <forename>
         Chian-Shiu
        </forename>
        <initials>
         CS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yarmishyn
        </lastname>
        <forename>
         Aliaksandr A
        </forename>
        <initials>
         AA
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Yi-Ying
        </forename>
        <initials>
         YY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Luo
        </lastname>
        <forename>
         Yung-Hung
        </forename>
        <initials>
         YH
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Chest Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Yi-Tsung
        </forename>
        <initials>
         YT
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lai
        </lastname>
        <forename>
         Wei-Yi
        </forename>
        <initials>
         WY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         De-Ming
        </forename>
        <initials>
         DM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chou
        </lastname>
        <forename>
         Shih-Jie
        </forename>
        <initials>
         SJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Yi-Ping
        </forename>
        <initials>
         YP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Mong-Lien
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chiou
        </lastname>
        <forename>
         Shih-Hwa
        </forename>
        <initials>
         SH
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Genomic Research Center, Academia Sinica, Taipei 11529, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Switzerland
      </country>
      <medlineta>
       Int J Mol Sci
      </medlineta>
      <nlmuniqueid>
       101092791
      </nlmuniqueid>
      <issnlinking>
       1422-0067
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000669933">
        COVID-19 vaccine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D007155">
        Immunologic Factors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D014765">
        Viral Vaccines
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705128">
       COVID-19 serotherapy
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000235">
        genetics
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002986">
        Clinical Trials as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000517">
        prevention &amp; control
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D016679">
        Genome, Viral
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007116">
        Immunization, Passive
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007155">
        Immunologic Factors
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D014765">
        Viral Vaccines
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ACE2
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       clinical trials
      </keyword>
      <keyword majortopicyn="N">
       immunotherapy
      </keyword>
      <keyword majortopicyn="N">
       pneumonia
      </keyword>
      <keyword majortopicyn="N">
       replicase
      </keyword>
      <keyword majortopicyn="N">
       vaccine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        12
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32290293
      </articleid>
      <articleid idtype="pii">
       ijms21072657
      </articleid>
      <articleid idtype="doi">
       10.3390/ijms21072657
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
  </pubmedarticleset>
 </body>
</html>